IAPT Rec'd PCT/PTO 06 APR 2006


FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 7-2005) . TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

RLL-444US

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 10/57505/											
NTERNATIONAL APPLICATION NO.			INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED							
PCT/IB2004/003272 7 October 2004 (7.10.2004) 08 October 2003 (08.10.2003)											
ITLE OF INVENTION ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF SERTRALINE											
APPLICANT(S) FOR DO/EO/US											
Raheja et al.											
applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:											
1.	\boxtimes	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.									
2.		This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.									
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.									
4.		The US has been elected (Article 31).									
5.	\boxtimes	A copy of the International Applica	ation as filed (35 U.S.C. 371 (c)(2))								
		a. is attached hereto (required only if not communicated by the International Bureau).									
		b. 🖾 has been communicated by the International Bureau.									
		c. is not required, as the application was filed in the United States Receiving Office (RO/US).									
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).									
		a. is attached hereto.									
		b. has been previously sub	mitted under 35 U.S.C. 154(d)(4).	,							
7.		Amendments to the claims of the	International Application under PCT Article 19	(35 U.S.C. 371 (c)(3))							
		a. are attached hereto (req	uired only if not communicated by the Internati	onal Bureau).							
		b. have been communicated by the International Bureau.									
			wever, the time limit for making such amendm	ents has NOT expired.							
_	_	d. have not been made and will not be made.									
8.			f the amendments to the claims under PCT Ar	ticle 19 (35 U.S.C. 371(c)(3)).							
9.	\boxtimes	An oath or declaration of the inver		Timeria dia Rapadanda ROT							
10.	Ц	An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).									
11.		A copy of the International Prelimi	nary Examination Report (PCT/IPEA/409).								
12.	\boxtimes	A copy of the International Search	Report (PCT/ISA/210).								
Ite	ems 1	3 to 23 below concern document	(s) or information included:								
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.									
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.									
15.		A FIRST preliminary amendment.									
16.		A SECOND or SUBSEQUENT preliminary amendment.									
17.		A substitute specification.									
18.		A power of attorney and/or change of address letter.									
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.									
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).									
21.		A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).									
22.	\boxtimes	Express Mail Label No. EV	483375588 US								



PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NUMBER PCT/IB2004/003272 **RLL-444US** 23. Return Post Card **CALCULATIONS PTO USE** The following fees have been submitted: 24. \$300 \$ \$300.00 Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report \$ \$200.00 prepared by IPEA/US indicates all claims satisfy provisions of PCT Article \$0 \$200 Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4). . . \$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the \$400.00 as an International Searching Authority..... \$100 International Search Report prepared by an ISA other than the US and provided to the previously communicated to the US by the IB...... \$400 TOTAL OF 24, 25 and 26 = \$900.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)).

The fee is \$250 for each additional 50 sheets of paper or fraction thereof. **Total Sheets** Number of each additional 50 or Extra Sheets RATE fraction thereof (round up to a whole - 100 = 0 /50 = \$ \$0.00 13 \$250.00 Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)). NUMBER FILED NUMBER EXTRA RATE CLAIMS Total claims 30 - 20 = 10 \$50.00 \$500.00 х Independent claims 3 х \$200.00 \$0.00 MULTIPLE DEPENDENT CLAIMS (if applicable) + \$360.00 \$0.00 **TOTAL OF ABOVE CALCULATIONS =** \$ \$1,400.00 Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2. \$ \$0.00 SUBTOTAL = \$ \$1,400.00 Processing fee of \$130.00 for furnishing the English translation later than 30 months from \$0.00 the earliest claimed priority date (37 CFR 1.492(i)). \$1,400.00 TOTAL NATIONAL FEE = Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be \$0.00 accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property \$1,400.00 TOTAL FEES ENCLOSED = Amount to be \$

\$

Amount to be

					10/	9 PIO-1830 (Rev. 07-2005)			
Und	er the	Paperwork Reduction Act of 1995, no persons are re	equired to respond	U.S. Patent and Tr	Approved for use throi ademark Office; U.S. Dormation unless it displa	EPARTMENT OF COMMERCE			
a.		A check in the amount of \$	to cover the	abova jees isjen	losed Doran	OG APR 2006			
b.	\boxtimes	Please charge my Deposit Account No. A duplicate copy of this sheet is enclosed.	50-0912	in the amount of	\$ \$1,400.00	to cover the above fees.			
C.	\boxtimes	The Commissioner is hereby authorized to to Deposit Account No. 50-0912	• •	tional fees which noopy of this sheet is	•	credit any overpayment			
d.	d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status,									
SE	ND A	ALL CORRESPONDENCE TO:			tillies H	910			
Customer NO. 26815				SIGNA	SIGNATURE				
				Willi	am D. H are, Esq.	•			
				NAME	NAME				
				44,73	44,739				
				REGIS	TRATION NUMBER	₹			
				April	6, 2006				
				DATE					

10/575057 RLL-444US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

RAHEJA et al.

Application No.:

TBA

Filing Date:

TBA

Title:

ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF

SERTRALINE

CERTIFICATE OF EXPRESS MAILING

I hereby certify that the following correspondence:

- Transmittal Letter to the United States Designated/Elected Office (DO/EO/US)
- Unexecuted Combined Declaration and Power of Attorney
- Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on April 6, 2006.

Michelle Morgan

Name of Person Mailing Correspondence

Michelle Morgan

Michelle Morgan

Correspondence

Signature

EV 483375588US

"Express Mail" Mailing Label Number